-
公开(公告)号:WO2007092751A3
公开(公告)日:2007-12-27
申请号:PCT/US2007061515
申请日:2007-02-02
Applicant: LILLY CO ELI , BELL MICHAEL GREGORY , GENIN MICHAEL JAMES , LANDER PETER AMBROSE , STELZER LINDSAY SCOTT , DOTI ROBERT ANTHONY , AGEJAS-CHICHARRO FRANCISCO JAV , BUENO MELENDO ANA BELEN , MANNINEN PETER RUDOLPH , OCHOADA JASON MATTHEW , SHEN QUANRONG , WARSHAWSKY ALAN M , MA TIANWEI , STITES RYAN EDWARD
Inventor: BELL MICHAEL GREGORY , GENIN MICHAEL JAMES , LANDER PETER AMBROSE , STELZER LINDSAY SCOTT , DOTI ROBERT ANTHONY , AGEJAS-CHICHARRO FRANCISCO JAV , BUENO MELENDO ANA BELEN , MANNINEN PETER RUDOLPH , OCHOADA JASON MATTHEW , SHEN QUANRONG , WARSHAWSKY ALAN M , MA TIANWEI , STITES RYAN EDWARD
IPC: C07D413/12 , A61K31/42 , A61K31/427 , A61P3/06 , C07D413/14 , C07D417/12
CPC classification number: C07D413/12 , C07D413/14 , C07D417/12
Abstract: Compounds of formula and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.
Abstract translation: 公开的化合物及其药物组合物和使用方法被公开用于治疗血脂异常和相关疾病。
-
公开(公告)号:WO2005051893A2
公开(公告)日:2005-06-09
申请号:PCT/US2004/037182
申请日:2004-11-16
Applicant: ELI LILLY AND COMPANY , BUNEL, Emilio, Enrique , GAJEWSKI, Robert, Peter , JONES, Charles, David , LU, Jianliang , NAGPAL, Sunil , MA, Tianwei , YEE, Ying, Kwong
Inventor: BUNEL, Emilio, Enrique , GAJEWSKI, Robert, Peter , JONES, Charles, David , LU, Jianliang , NAGPAL, Sunil , MA, Tianwei , YEE, Ying, Kwong
IPC: C07C235/00
CPC classification number: C07C235/42 , C07C65/19 , C07C69/92 , C07C235/84 , C07C2601/08 , C07C2601/14 , C07D257/04 , C07D257/06
Abstract: The present invention relates to novel, non-secosteroidal, hydroxyl substituted, carbon- linked diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.
Abstract translation: 本发明涉及具有维生素D受体(VDR)调节活性的新颖的非甾体,羟基取代的碳键二芳基化合物,其比1α,25二羟基维生素D3低钙血红素。 这些化合物可用于治疗骨病和牛皮癣。
-
3.
公开(公告)号:WO2023025092A1
公开(公告)日:2023-03-02
申请号:PCT/CN2022/113921
申请日:2022-08-22
Applicant: BIOFRONT LTD (CAYMAN) , MA, Tianwei
Inventor: FANG, Lichao , SHI, Feng , XUE, Wei , LIU, Miao , HUANG, Zheng
IPC: C07D401/14 , C07D413/14 , C07D417/14 , C07D471/04 , A61K31/497 , A61K31/395 , A61P35/00
Abstract: The present disclosure provides compounds of Formula I', compositions comprising the compound of Formula I', and methods of using the same, in treating diseases, disorders, or conditions mediated by the inhibition of certain kinases, such as hematopoietic progenitor kinase 1 (HPK1) and/or Fms related receptor tyrosine kinases (FLTs), such as FLT3.
-
公开(公告)号:WO2023025091A1
公开(公告)日:2023-03-02
申请号:PCT/CN2022/113919
申请日:2022-08-22
Applicant: BIOFRONT LTD (CAYMAN) , MA, Tianwei
Inventor: FANG, Lichao , SHI, Feng , WANG, Yayi , XUE, Wei , LIU, Miao , HUANG, Zheng
IPC: C07D403/14 , A61K31/437 , A61P35/00
Abstract: Provided compounds of Formula I and I', pharmaceutical compositions comprising the compounds, and methods of using the same, in treating, for example, the diseases, disorders, or conditions mediated by the degradation of a protein kinase, such as Hematopoietic progenitor kinase 1(HPK1).
-
公开(公告)号:WO2022193187A1
公开(公告)日:2022-09-22
申请号:PCT/CN2021/081363
申请日:2021-03-17
Applicant: BIOFRONT LTD. (CAYMAN) , MA, Tianwei
Inventor: SHI, Feng , HUANG, Zheng , LIN, Hua Viola , XIAO, Yue
IPC: C07D403/04 , C07D405/04 , C07D231/42 , C07D261/16 , C07D277/52 , C07D333/36 , C07D307/66 , A61K31/4155 , A61K31/422 , A61K31/427 , A61K31/381 , A61K31/341 , A61P25/14
Abstract: Compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating diseases, disorders of conditions mediated by the signaling of formyl peptide receptor 1 (FPR1).
-
公开(公告)号:WO2004063166A1
公开(公告)日:2004-07-29
申请号:PCT/US2003/039119
申请日:2003-12-31
Applicant: ELI LILLY AND COMPANY , CONNER, Scott, Eugene , MA, Tianwei , MANTLO, Nathan, Bryan , MAYHUGH, Daniel, Ray , SCHKERYANTZ, Jeffrey, Michael , WARSHAWSKY, Alan, M. , ZHU, Guoxin
Inventor: CONNER, Scott, Eugene , MA, Tianwei , MANTLO, Nathan, Bryan , MAYHUGH, Daniel, Ray , SCHKERYANTZ, Jeffrey, Michael , WARSHAWSKY, Alan, M. , ZHU, Guoxin
IPC: C07D231/12
CPC classification number: C07D231/12 , C07D233/20 , C07D233/22 , C07D233/64 , C07D249/06 , C07D253/04 , C07D261/08
Abstract: The present invention is directed to compounds represented by the following structural formula, Formula I: wherein: (a) X is selected from the group consisting of a single bond, O, S, S(O)2 and N; (b) U is an aliphatic linker; (c) Y is selected from the group consisting of O, C, S, NH and a single bond; (d) E is C(R3)(R4)A or A and wherein (i) A is selected from the group consisting of carboxyl, tetrazole, C1-C6 alkylnitrile, carboxamide, sulfonamide and acylsulfonamide; (e) Z1 and Z2 are each independently selected from the group consisting of N, O, and C with the proviso that at least one of Z1 and Z2 is N; (f) Z3 is selected from the group consisting of N, O, and C. (g) R8 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C4 alkylenyl and halo; (h) R9 is selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 alkylenyl, halo, aryl- C0-C4 alkyl, heteroaryl, C1-C6 allyl, and OR29.
Abstract translation: 本发明涉及由以下结构式(I)表示的化合物:其中:(a)X选自单键,O,S,S(O)2和N; (b)U是脂族连接体; (c)Y选自O,C,S,NH和单键; (d)E是C(R3)(R4)A或A,其中(i)A选自羧基,四唑,C 1 -C 6烷基腈,甲酰胺,磺酰胺和酰基磺酰胺; (e)Z1和Z2各自独立地选自N,O和C,条件是Z1和Z2中的至少一个是N; (f)Z 3选自N,O和C.(g)R 8选自氢,C 1 -C 6烷基,C 1 -C 4亚烷基和卤素; (h)R 9选自氢,C 1 -C 4烷基,C 1 -C 4亚烷基,卤素,芳基-C 0 -C 4烷基,杂芳基,C 1 -C 6烯丙基和OR 29。
-
7.
公开(公告)号:WO2023023941A1
公开(公告)日:2023-03-02
申请号:PCT/CN2021/114321
申请日:2021-08-24
Applicant: BIOFRONT LTD (CAYMAN) , MA, Tianwei
Inventor: XUE, Wei , SHI, Feng , HUANG, Zheng
IPC: A61K47/55 , C07D209/34 , C07D401/04 , C07D403/14 , C07D471/04 , C07D487/04 , A61K31/437 , A61K31/4985 , A61P35/00
Abstract: Provided are compounds of Formula I, compositions comprising the compounds of Formula I, and methods of using the same, in treating, for example, the diseases, disorders, or conditions mediated by the degradation of hematopoietic progenitor kinase 1 (HPK1).
-
公开(公告)号:WO2022194240A1
公开(公告)日:2022-09-22
申请号:PCT/CN2022/081416
申请日:2022-03-17
Applicant: BIOFRONT LTD. (CAYMAN) , MA, Tianwei
Inventor: SHI, Feng , FANG, Lichao , HUANG, Zheng , LIN, Hua Viola , XIAO, Yue
IPC: C07D403/04 , C07D405/04 , C07D231/42 , C07D261/16 , C07D277/52 , C07D333/36 , C07D307/66 , A61K31/4155 , A61K31/422 , A61K31/427 , A61K31/381 , A61K31/341 , A61P25/14
Abstract: Compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating diseases, disorders of conditions mediated by the signaling of formyl peptide receptor 1 (FPR1).
-
9.
公开(公告)号:WO2008103574A3
公开(公告)日:2008-12-18
申请号:PCT/US2008053653
申请日:2008-02-12
Applicant: LILLY CO ELI , PFEIFER LANCE ALLEN , MA TIANWEI , MANTLO NATHAN BRYAN , MICHAEL LAURA FREY , MOKUBE FESE MAMBO , MONTROSE-RAFIZADEH CHAHRZAD
Inventor: PFEIFER LANCE ALLEN , MA TIANWEI , MANTLO NATHAN BRYAN , MICHAEL LAURA FREY , MOKUBE FESE MAMBO , MONTROSE-RAFIZADEH CHAHRZAD
IPC: C07D249/12 , A61K31/4196 , A61K31/4439 , A61P3/00 , C07D401/06
CPC classification number: C07D401/06 , C07D249/12
Abstract: The present invention is directed to compounds of the structural Formula: wherein: R1 is H or -C1-C3 alkyl; R2 is selected from the group consisting of -H, -C1-C4 alkyl, -C1-C3 alkyl-CF3, phenyl, and pyridinyl; and R3 is selected from the group consisting of -H, -C1-C4 alkyl, -C1-C3 alkyl-O-CH3, -CH2-cyclopropyl, -CH2-C=CH2, -CH2CH2-(2-F-phenyl), and phenyl substituted with from 1 to 2 fluorines; provided that when R1 and R2 are each H, then R3 is selected from the group consisting of -C1-C4 alkyl, -C1-C3 alkyl-O-CH3, -CH2-cyclopropyl, -CH2-C=CH2, -CH2CH2-(2-F-phenyl), and phenyl substituted with from 1 to 2 fluorines; or stereoisomers and pharmaceutically acceptable salts thereof.
Abstract translation: 本发明涉及结构式的化合物:其中:R 1是H或-C 1 -C 3烷基; R 2选自-H,-C 1 -C 4烷基,-C 1 -C 3烷基-CF 3,苯基和吡啶基; 并且R 3选自-H,-C 1 -C 4烷基,-C 1 -C 3烷基-O-CH 3,-CH 2 - 环丙基,-CH 2 -C = CH 2,-CH 2 CH 2 - (2-F-苯基) 和被1至2个氟取代的苯基; 条件是当R 1和R 2各自为H时,R 3选自-C 1 -C 4烷基,-C 1 -C 3烷基-O-CH 3,-CH 2 - 环丙基,-CH 2 -C = CH 2,-CH 2 CH 2 - (2-F-苯基)和被1至2个氟取代的苯基; 或其立体异构体及其药学上可接受的盐。
-
公开(公告)号:WO2007092751A2
公开(公告)日:2007-08-16
申请号:PCT/US2007/061515
申请日:2007-02-02
Applicant: ELI LILLY AND COMPANY , BELL, Michael, Gregory , GENIN, Michael, James , LANDER, Peter, Ambrose , STELZER, Lindsay, Scott , DOTI, Robert, Anthony , AGEJAS-CHICHARRO, Francisco, Javier , BUENO MELENDO, Ana, Belen , MANNINEN, Peter, Rudolph , OCHOADA, Jason, Matthew , SHEN, Quanrong , WARSHAWSKY, Alan, M. , MA, Tianwei , STITES, Ryan, Edward
Inventor: BELL, Michael, Gregory , GENIN, Michael, James , LANDER, Peter, Ambrose , STELZER, Lindsay, Scott , DOTI, Robert, Anthony , AGEJAS-CHICHARRO, Francisco, Javier , BUENO MELENDO, Ana, Belen , MANNINEN, Peter, Rudolph , OCHOADA, Jason, Matthew , SHEN, Quanrong , WARSHAWSKY, Alan, M. , MA, Tianwei , STITES, Ryan, Edward
IPC: C07D413/12 , C07D413/14 , C07D417/12 , A61K31/42 , A61K31/427 , A61P3/06
CPC classification number: C07D413/12 , C07D413/14 , C07D417/12
Abstract: Compounds of formula. wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.
Abstract translation: 式的化合物。 其中变量如本文所定义,并且其药物组合物和使用方法被公开用于治疗血脂异常和相关疾病。
-
-
-
-
-
-
-
-
-